Mereo BioPharma (MREO) Non-Current Debt (2017 - 2021)

Mereo BioPharma (MREO) has 5 years of Non-Current Debt data on file, last reported at $19.4 million in Q4 2021.

• Non-Current Debt for Q4 2021 came in at $19.4 million, down 9.03% year-over-year; the trailing twelve-month figure through Dec 2021 was $19.4 million (down 9.03% YoY), and the FY2021 annual result was $19.4 million, down 9.03% from the prior year.
• Non-Current Debt slipped to $19.4 million in Q4 2021 per MREO's latest filing, from $21.3 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $25.0 million in Q4 2017 and troughed at $6.9 million in Q4 2019.
• A 5-year average of $18.3 million and a median of $19.4 million in 2021 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2019 and 2020: Non-Current Debt tumbled 63.35% in 2019, then jumped 208.54% in 2020.
• A 5-year view of Non-Current Debt shows it stood at $25.0 million in 2017, then decreased by 24.54% to $18.8 million in 2018, then plunged by 63.35% to $6.9 million in 2019, then jumped by 208.54% to $21.3 million in 2020, then slipped by 9.03% to $19.4 million in 2021.
• Business Quant data shows MREO's Non-Current Debt at $19.4 million in Q4 2021, $21.3 million in Q4 2020, and $6.9 million in Q4 2019.